Trial Profile
A Phase 3b Open-label Study to Determine the Long-term Safety and Efficacy of Vedolizumab Subcutaneous in Subjects With Ulcerative Colitis and Crohn's Disease
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Vedolizumab (Primary) ; Vedolizumab
- Indications Crohn's disease; Ulcerative colitis
- Focus Adverse reactions; Registrational
- Acronyms VISIBLE OLE
- Sponsors Takeda; Takeda Development Centre Europe
- 08 Mar 2024 This trial has been completed in Slovakia, according to European Clinical Trials Database record.
- 05 Jan 2024 Planned End Date changed from 4 Jan 2024 to 21 Jun 2024.
- 05 Jan 2024 Planned primary completion date changed from 4 Jan 2024 to 4 Apr 2024.